A Study to Assess New Formulations of TEV-56286

Study Title
An Open-Label, Randomized, Crossover Study to Assess the Comparative Bioavailability of New TEV-56286 Formulations Compared to a Reference TEV-56286 Capsule Formulation Following Single-Dose Administration in Healthy Participants
Teva Identifier
TV56286-BA-10218
ClinicalTrials.gov Identifier
NCT06911567
Study Status
Completed
Trial Condition(s)
Healthy Participants
Interventions
Drug: TEV-56286 Test | Drug: TEV-56286 Reference
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
brain-icon

Key Participation Requirements

Gender
Female, Male
Age group
Adult
Age Range
18 years to 60 Years
Trial Duration
10 March 2025 - 02 June 2025
Phase
Phase 1

Study Type

Interventional